JPMorgan Revises #HIMS Outlook as Regulatory and Execution Risks
JPMorgan has taken a fresh look at Hims & Hers Health (NYSE: HIMS), resuming coverage of the stock with a Neutral rating and a $32 price target. The decision reflects a more complicated growth path for the direct-to-consumer telehealth company, especially as regulatory pressure continues to reshape its weight-loss business. The $32 target implies roughly 17% upside from the Sept. 10 close. However, JPMorgan is not yet ready to adopt a more bullish stance. The bank wants clearer evidence that Hims & Hers can successfully transition away from compounded GLP-1 drugs and toward branded treatments without sacrificing margins along the way. Hims & Hers operates a direct-to-consumer telehealth platform that offers treatments across a wide range of categories, including weight loss, sexual health, dermatology, mental health, and other areas. The company generates revenue primarily through subscriptions and prescription medications delivered through its digital platform. That model has helped Hims & Hers build a broad consumer-facing healthcare brand, but it also leaves the company exposed to regulatory changes and competitive pressures, particularly in the high-profile weight-loss segment. JPMorgan analyst Brian Smilek had previously rated the shares Overweight before coverage was suspended in June. While he remains constructive on Hims & Hers’ vertical integration and its expansion into new specialties and international markets, he is now taking a more measured view. Smilek said the firm is looking for execution across several key areas: the strategic transition toward branded GLP-1s, durability of growth across newer specialties, deeper international penetration, and durable margin expansion. JPMorgan also sees peptides as another potential growth opportunity for Hims & Hers. That could provide an additional avenue for expansion if the company can capitalize on it. But until Hims & Hers proves that its transition can support both revenue growth and durable margin expansion, the $32 price target suggests that upside may remain constrained by execution risk. The Neutral rating captures this balanced view: JPMorgan is not issuing a negative call, but it is also not signaling strong conviction. The firm appears to see the risk/reward as roughly balanced at current levels. The key risk is that regulatory pressure could make the weight-loss business harder to navigate, while the key opportunity is that a successful shift toward branded GLP-1s, combined with expansion into new specialties and international markets, could unlock further growth. Until then, the stock may be judged more by execution milestones than by broad enthusiasm.
